Logotype for Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals (ELDN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Eledon Pharmaceuticals Inc

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Tegoprubart, an anti-CD40L antibody, remains the focus of development in kidney and islet transplantation; no products are approved and no product sales revenue has been generated.

  • Q3 net loss narrowed to $3.9M from $17.5M, mainly due to a $17.0M non-cash warrant-liability fair-value gain; operating expenses increased to $21.7M.

  • Kidney-transplant extension data showed higher eGFR with tegoprubart than tacrolimus through month 24; planned registrational trials remain dependent on additional financing.

Financial highlights

  • Q3 R&D expense was $17.8M vs. $15.0M a year earlier; G&A was $3.9M vs. $4.1M, and operating expenses totaled $21.7M vs. $19.1M.

  • Q3 net loss was $3.9M, or $0.03 per share, vs. $17.5M, or $0.21 per share; excluding warrant fair-value changes, Q3 net loss was $21.0M vs. $18.0M.

  • 9M operating expenses were $65.7M vs. $61.8M, and net loss was $74.6M vs. $35.2M; warrant remeasurement shifted from a $22.9M gain to an $11.6M loss.

  • 9M operating cash use was $64.3M vs. $48.3M; quarter-end cash and equivalents were $6.9M, while cash, equivalents and short-term investments totaled $69.7M.

Outlook and guidance

  • Global Phase 3 LEGACY in kidney transplantation is planned for Q4 2026, subject to financing; expected enrollment is ~600, with a week-52 non-inferiority endpoint based on BPAR, graft loss and death.

  • FDA cleared the IND for a planned company-sponsored registrational-path islet-transplant study; initiation requires additional financing.

  • Other planned programs include an investigator-led de novo liver-transplant study; FDA guidance on the kidney xenotransplantation path to market is anticipated over the next 12 months.

  • Manufacturing and personnel costs are expected to rise as kidney Phase 3 and islet programs advance; current resources are not expected to fund planned operations for at least 12 months from financial-statement issuance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Eledon Pharmaceuticals